Outcomes27

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 20 of 27

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Cmax for Lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7	All subjects with evaluable concentrations	ng/mL	MEAN
PRIMARY	Tmax for Lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7	All subjects with evaluable concentrations	hr	MEDIAN
PRIMARY	AUC0-t for Lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7	All subjects with evaluable concentrations	ng*hr/mL	MEAN
PRIMARY	AUC0-∞ for Lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7	AUC0-∞ and t1/2 were not calculated for 3 subjects in the Japanese 10mg arm because the estimated t1/2 was being much longer than half of the total sampling time.	ng*hr/mL	MEAN
PRIMARY	t1/2 for Lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7	AUC0-∞ and t1/2 were not calculated for 3 subjects in the Japanese 10mg arm because the estimated t1/2 was being much longer than half of the total sampling time.	hr	MEAN
PRIMARY	Cmax for Lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27	All subjects with evaluable concentrations	ng/mL	MEAN
PRIMARY	Tmax for Lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27	All subjects with evaluable concentrations	hr	MEDIAN
PRIMARY	AUC0-t for Lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27	All subjects with evaluable concentrations	ng*hr/mL	MEAN
PRIMARY	t1/2 for Lomitapide	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27	All subjects with evaluable concentrations	hr	MEAN
SECONDARY	Cmax for M1	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7	All subjects with evaluable concentrations	ng/mL	MEAN
SECONDARY	Tmax for M1	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7	All subjects with evaluable concentrations	hr	MEDIAN
SECONDARY	AUC0-t for M1	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7	All subjects with evaluable concentrations	ng*hr/mL	MEAN
SECONDARY	AUC0-∞ for M1	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7	All subjects with evaluable concentrations	ng*hr/mL	MEAN
SECONDARY	t1/2 for M1	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7	All subjects with evaluable concentrations	hr	MEAN
SECONDARY	Cmax for M3	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7	All subjects with evaluable concentrations	ng/mL	MEAN
SECONDARY	Tmax for M3	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7	All subjects with evaluable concentrations	hr	MEDIAN
SECONDARY	AUC0-t for M3	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7	All subjects with evaluable concentrations	ng*hr/mL	MEAN
SECONDARY	AUC0-∞ for M3	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7	All subjects with evaluable concentrations	ng*hr/mL	MEAN
SECONDARY	t1/2 for M3	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 7	All subjects with evaluable concentrations	hr	MEAN
SECONDARY	Cmax for M1	1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours postdose on Day 27	All subjects with evaluable concentrations	ng/mL	MEAN

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01760187/outcomes

API reference For AI assistants

Outcomes27

Sources 3

Read this list from software.